Search for Clinical Trial Results

Sponsored By

Neuromyelitis Optica - 50 Studies Found

Status Study
Completed Study Name: Neuromyelitis Optica (NMO) & Cetirizine
Condition: Neuromyelitis Optica
Date: 2016-08-09
Interventions: Drug: cetirizine Other Name: Zyrtec
Completed Study Name: Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
Condition: Neuromyelitis Optica
Date: 2014-03-11
Interventions:
  • Drug: Alpha1-antitrypsin Other
Active, not recruiting Study Name: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Date: 2011-04-18
Interventions: Procedure: AHSCT AHSCT Procedure:
Completed Study Name: C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
Condition: Neuromyelitis Optica
Date: 2012-12-29
Interventions: Drug: C1-esterase inhibitor (Cinryze) Other Name: Cinryze
Completed Study Name: Safety and Tolerability of Rituximab in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Date: 2007-07-12
Interventions: Drug: Rituximab Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular m
Completed Study Name: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Condition: Neuromyelitis Optica Spectrum Disorder
Date: 2013-04-26
Interventions: Drug: NPB-01 Other Name: Intravenous immunoglobulin
Completed Study Name: Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
Condition:
  • Neuromyelitis Optica
  • Neuromyelitis Optica
    Date: 2013-09-03
    Interventions: Drug: Mitoxantrone The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 month
Completed Study Name: An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Condition:
  • Neuromyelitis Optica
  • Devic's Disease Date: 2009-05-18
    Interventions: Drug: Eculizumab The patient will receive eculizumab at a
Active, not recruiting Study Name: Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Condition:
  • Neuromyelitis Optica
  • Neuromyelitis Optica
    Date: 2014-10-21
    Interventions: Drug: Ublituximab Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which
Active, not recruiting Study Name: Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Condition: Neuromyelitis Optica Spectrum Disorder
Date: 2016-08-27
Interventions: Drug: Bortezomib Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of
Next >>>